Last update July 27, 2022
Very Low Risk
S - (+) active enantiomer of ketoprofen with similar structure, pharmacokinetics and anti-inflammatory, anti-allergic and antipyretic properties (Valles 2006, Barbanoj 2001). Oral or intravenous administration in two - three daily doses. Also used as a gel or cream for topical use.
Since the last update we have not found published data on its excretion in breastmilk. But it is presumed to be similar to that of its enantiomer, ketoprofen, whose excretion in milk is insignificant (Jacqz-Aigrain 2007). Its high percentage of protein binding and short half-life make it unlikely it will transfer into breastmilk in significant amounts.
Most nonsteroidal anti-inflammatory drugs can increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of infants with jaundice. (Janssen 2000).
Because there is less published information than with other drugs in the same group, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
TOPICAL USE: The forms of cutaneous application have very low systemic absorption through the skin and are compatible with breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM